Engineering Stream


The State of the Science in Biotherapeutics Research and Development 

Antibody research in response to the COVID-19 pandemic has crash-tested new discovery technologies and caused the industry to find new ways of conducting discovery and development faster and more efficiently. With this as a foundation, the PEGS Engineering Stream examines the state of the science in biologics R&D, including smarter and higher throughput screening methods, new technologies to accelerate and optimize antibody engineering and the increasing role of machine learning in discovery and engineering. The Stream also explores developments in therapeutic antibodies for neurodegeneration, autoimmunity, cardiovascular disease and infectious diseases. Plan to join these essential tracks and see why PEGS has become the industry’s must-attend event in biotherapeutics R&D.


Conferences Include:

May 2-3

Display of Biologics

May 3-4

Engineering Antibodies

May 5-6

Machine Learning Approaches for Protein Engineering

Keynote Presentations:

Protein Structure Prediction in a Post-AlphaFold2 World
Mohammed AlQuraishiMohammed AlQuraishi, PhD, Assistant Professor, Systems Biology, Columbia University

How Structure-Based Machine Learning Can Drive the Development of Biotherapeutics
Charlotte M. DeaneCharlotte M. Deane, PhD, Professor of Structural Bioinformatics, Statistics, University of Oxford

From Alpha to Epsilon: A Global Consortium Study to Define Variant Resistant Epitopes on SARS-CoV-2 Spike
Kathryn M. HastieKathryn M. Hastie, PhD, Instructor, La Jolla Institute for Immunology

Applications of Nanobodies to Laboratory Diagnosis
Serge MuyldermansSerge Muyldermans, PhD, Professor & Group Leader, Cellular & Molecular Immunology Lab, Vrije University Brussels